Fluoxetine & Metoprolol Interaction

Fluoxetine (Prozac) is a potent inhibitor of cytochrome P450 2D6 (CYP2D6), the primary enzyme responsible for metabolizing metoprolol (Lopressor, Toprol-XL), and can increase metoprolol plasma concentrations by 3-8 fold, potentially converting a patient from a normal CYP2D6 metabolizer to a phenocopy of a CYP2D6 poor metabolizer ^[1]. The resulting elevated metoprolol levels can cause excessive beta-adrenergic blockade, manifesting as symptomatic bradycardia, hypotension, fatigue, dizziness, and in severe cases, heart block or cardiogenic shock ^[2]. This interaction is clinically important because both medications are among the most commonly prescribed drugs — fluoxetine for depression and anxiety, and metoprolol for hypertension, heart failure, and cardiac arrhythmias — and co-prescription is common in patients with comorbid cardiovascular and psychiatric conditions ^[3].

The magnitude of this interaction is substantial and underappreciated. While many CYP2D6 interactions are modest (20-50% changes in drug levels), fluoxetine's potent and persistent CYP2D6 inhibition can produce dramatic metoprolol level increases that fundamentally change the drug's clinical profile ^[1].

Metoprolol is extensively metabolized by CYP2D6 in the liver, with approximately 70-80% of an oral dose undergoing first-pass metabolism ^[1]. CYP2D6 is responsible for alpha-hydroxylation and O-demethylation of metoprolol, the major elimination pathways ^[2]. Fluoxetine and its active metabolite norfluoxetine are among the most potent clinically relevant inhibitors of CYP2D6, with inhibition constants (Ki) in the low nanomolar range ^[1]. When CYP2D6 is inhibited by fluoxetine, metoprolol's oral bioavailability increases dramatically (from approximately 50% to >80%) and its elimination half-life extends from 3-7 hours to 10-20 hours, resulting in 3-8 fold increases in steady-state plasma concentrations ^[2].

Critically, norfluoxetine (fluoxetine's active metabolite) has a half-life of 4-16 days, meaning that CYP2D6 inhibition persists for weeks after fluoxetine is discontinued ^[1]. This has important implications for patients who stop fluoxetine but remain on metoprolol — the interaction effect gradually resolves over 3-5 weeks, during which metoprolol levels slowly decrease and dose adjustments may be needed ^[3].

Case reports have documented severe symptomatic bradycardia (heart rate <40 bpm), hypotension, syncope, and heart block in patients on metoprolol who started fluoxetine ^[2]. A pharmacokinetic study demonstrated that fluoxetine 20 mg daily increased the AUC of metoprolol by 3.8-fold and the Cmax by 3.4-fold in CYP2D6 extensive metabolizers ^[1]. The clinical significance extends beyond bradycardia: excessive beta-blockade can mask the symptoms of hypoglycemia in diabetic patients, worsen peripheral arterial disease, exacerbate bronchospasm in patients with reactive airway disease, and cause significant fatigue and exercise intolerance that may be misattributed to depression ^[3]. The interaction is most dangerous during the transition period — when fluoxetine is initiated in a patient on stable metoprolol, or when a patient stabilized on both drugs discontinues fluoxetine ^[1]. Approximately 7-10% of the Caucasian population are CYP2D6 poor metabolizers who already have minimal CYP2D6 activity — in these individuals, fluoxetine provides little additional enzyme inhibition, but baseline metoprolol levels are already elevated ^[2].

When starting fluoxetine in a patient on metoprolol, consider reducing the metoprolol dose by 50-75% and titrating based on heart rate and blood pressure response ^[1]. Monitor heart rate and blood pressure closely during the first 2-4 weeks of concurrent therapy ^[2]. Alternatively, switch metoprolol to a beta-blocker that is not dependent on CYP2D6 for metabolism: atenolol (renally eliminated), bisoprolol (mixed hepatic/renal), or nadolol (renally eliminated) are alternatives without this pharmacokinetic interaction ^[1]. If fluoxetine is the preferred SSRI, consider the combination with a non-CYP2D6 beta-blocker from the start ^[3]. When discontinuing fluoxetine, be aware that the interaction effect will persist for 3-5 weeks due to norfluoxetine's long half-life — gradually increase the metoprolol dose during this period if cardiovascular protection requires it ^[1]. Alternatively, switch fluoxetine to an SSRI with less CYP2D6 inhibition: sertraline, escitalopram, or citalopram have minimal CYP2D6 effects ^[2].

Monitor heart rate and blood pressure at baseline and at 1, 2, and 4 weeks after starting fluoxetine in a patient on metoprolol ^[1]. A resting heart rate below 50 bpm or symptomatic bradycardia requires metoprolol dose reduction ^[2]. Blood pressure should be checked both sitting and standing to detect orthostatic hypotension ^[3]. Obtain an ECG if the patient develops bradycardia to assess for heart block (prolonged PR interval, second-degree or third-degree AV block) ^[1]. Monitor for symptoms of excessive beta-blockade: unusual fatigue, cold extremities, dizziness, lightheadedness, exercise intolerance, vivid dreams or nightmares, and depression-like symptoms (which may be confused with the psychiatric condition being treated) ^[2]. In diabetic patients, monitor blood glucose more frequently, as beta-blocker excess can mask hypoglycemic symptoms (tachycardia, tremor) while allowing other signs (sweating, confusion) to persist ^[3]. Home blood pressure and heart rate monitoring is valuable for detecting the interaction between office visits ^[1].

Among beta-blockers, atenolol (Tenormin) is eliminated renally without CYP2D6 involvement and is a direct alternative for hypertension ^[1]. Bisoprolol (Zebeta) has mixed hepatic-renal elimination with less CYP2D6 dependence than metoprolol ^[2]. Among SSRIs, sertraline (Zoloft) has minimal CYP2D6 inhibitory activity and is a safer option to combine with metoprolol ^[2]. Escitalopram (Lexapro) and citalopram (Celexa) also have negligible CYP2D6 effects ^[1]. Bupropion (Wellbutrin) should be avoided as a fluoxetine alternative in this context, as it is also a potent CYP2D6 inhibitor that would cause the same interaction ^[3]. Venlafaxine (Effexor) is a weak CYP2D6 inhibitor at lower doses and is a moderate alternative, though some interaction may still occur at higher doses ^[2]. Mirtazapine (Remeron) has no significant CYP2D6 inhibition and is another antidepressant option ^[1]. Non-pharmacologic depression treatments (cognitive behavioral therapy, exercise, mindfulness-based approaches) should be integrated alongside medication management ^[3].